Amgen Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter and nine-month financial results for the period.

Key Highlights

  • Q3 2026 net income: $3,864 million, compared with $3,216 million in Q3 2025, according to the filing.
  • Q3 2026 total revenues: $10,365 million, up from $9,557 million in the prior-year quarter, with product sales of $9,883 million.
  • Diluted EPS (Q3 2026): $7.08, compared with $5.93 in Q3 2025, as reported in the condensed consolidated statements of income.
  • Nine-month net income: $8,058 million for the nine months ended September 30, 2026, versus $6,378 million for the same period in 2025.
  • Nine-month total revenues: $29,037 million for the first nine months of 2026, compared with $26,885 million in the prior-year period.
  • Shares outstanding: 540,911,490 shares of common stock as of October 29, 2026, per the filing cover page.
  • Q3 2026 R&D expense: $2,111 million, up from $1,900 million in Q3 2025.

Amgen's Third-Quarter 2026 Financial Results: Revenue Growth and Higher Income

According to the filing, Amgen reported total revenues of $10,365 million for the three months ended September 30, 2026, an increase from $9,557 million in the same quarter of 2025. Product sales accounted for $9,883 million of Q3 2026 revenues, compared with $9,137 million a year earlier. Other revenues were $482 million in Q3 2026 versus $420 million in Q3 2025.

The company disclosed total operating expenses of $6,655 million for Q3 2026, down from $7,031 million in Q3 2025. Cost of sales declined to $2,788 million from $3,082 million, while research and development expenses rose to $2,111 million from $1,900 million. Selling, general and administrative expenses were $1,680 million, compared with $1,720 million in the prior-year quarter. Operating income for Q3 2026 was $3,710 million, up from $2,526 million in Q3 2025, the filing stated.

For the nine months ended September 30, 2026, Amgen reported total revenues of $29,037 million and net income of $8,058 million, compared with $26,885 million and $6,378 million, respectively, for the same period in 2025. Diluted earnings per share for the nine-month period were $14.79, versus $11.77 in the prior-year period. The weighted-average diluted shares used in the nine-month EPS calculation were 545 million for 2026 and 542 million for 2025. Net interest expense for Q3 2026 was $653 million, and other income, net was $1,629 million, according to the filing. The provision for income taxes in Q3 2026 was $822 million. Amgen is listed on NASDAQ:AMGN.

What Was Disclosed

Amgen filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing Q3 and nine-month income statements, balance sheets, and comprehensive income figures, along with operating expense details and earnings per share data.